A major worry for many people right now is the Delta variant, a highly contagious strain of COVID-19 which is making headlines across the United States. The FDA has just authorized a third dose of the COVID-19 vaccine so that immune compromised patients can better protecting themselves from the virus. What does this mean for CKD, dialysis, and transplant patients? We spoke with Dr. Joseph Vassalotti, NKF Chief Medical Officer, in a recent Facebook Live to share the facts about the Delta variant, COVID-19 booster shots, and other concerns facing kidney patients.

In this episode, you will hear from:

Joseph A. Vassalotti, MD:

Nephrologist Joseph A. Vassalotti, MD, is the Chief Medical Officer of the National Kidney Foundation and Associate Clinical Professor of Medicine in the Division of Nephrology, at Icahn School of Medicine at Mount Sinai in New York, NY. He received his medical degree with Distinction in Research from the SUNY Stony Brook School of Medicine and completed an Internal Medicine Residency and Nephrology Fellowship at the Johns Hopkins Hospital. At NKF, his major focus is implementation of evidence-based clinical practice guidelines in chronic kidney disease (CKD), including the NKF’s Kidney Disease Outcomes Quality Initiative (KDOQI), particularly through guidance of the NKF’s primary care initiative, called CKDintercept. He has served as co-principal investigator for the U.S. Center for Disease Control and Prevention (CDC), demonstration project “CKD Health Evaluation and Risk Information Sharing” (CHERISH), which aimed to identify individuals at high risk for kidney disease in the U.S. and as an investigator for the U.S. National Institutes of Health (NIH) sponsored clustered practice randomized trial entitled, “Evidenced-Based Primary Care for Kidney Disease.”

For more resources on COVID-19 for kidney patients, visit www.kidney.org/coronavirus